They are the two ends of the "sexy women with giant animal companions" spectrum
#minaashiro #kn8 #tonakodogo #mgtx

I had to block so many stock marketing AI accounts here just to see the actual marriagetoxin posts in the #mgtx tag

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) Released

#MGTX MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

www.stocktitan.net/news/MGTX/meira-g-tx-rep...

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology MeiraGTx (Nasdaq: MGTX) announced a broad strategic collaboration with Eli Lilly on Nov 10, 2025 to develop and commercialize genetic medicines in ophthalmology.MeiraGTx granted Lilly worldwide exclusive rights to its AAV-AIPL1 program for LCA4 and exclusive access to in‑house intravitreal capsids, bespoke promoters (including AI‑generated promoters), and certain riboswitch technology for ocular gene editing. Clinical data reported that 11 children born legally blind gained vision after AAV-AIPL1, with additional developmental benefits described.Financial terms include a $75 million upfront payment, eligibility for over $400 million in milestones, and tiered royalties on licensed products.

#MGTX MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

www.stocktitan.net/news/MGTX/meira-g-tx-ent...

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results MeiraGTx (NASDAQ:MGTX), a clinical-stage genetic medicines company, reported significant progress across multiple programs in Q2 2025. The company achieved FDA alignment on its Phase 2 AQUAx2 study for radiation-induced xerostomia and received RMAT designation for AAV-GAD in Parkinson's disease treatment.Key developments include plans to file for Marketing Authorization Approval with MHRA and BLA with FDA for LCA4 treatment in Q4 2025. The company's strategic collaboration with Hologen includes $200 million in cash consideration and formation of Hologen Neuro AI Ltd joint venture with up to $230 million additional funding.Financial position shows $32.2 million in cash as of June 30, 2025, with additional receivables and expected proceeds sufficient to fund operations into 2027.

#MGTX MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

www.stocktitan.net/news/MGTX/meira-g-tx-rep...

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting MeiraGTx (Nasdaq: MGTX) presented four posters at the ASGCT 2025 Annual Meeting showcasing their gene and cell therapy technology platforms. Key presentations included: 1. An ultra-low dose CNS gene therapy for pediatric obesity using optimized BDNF clinical construct, showing 40% weight loss in mice vs 12% with semaglutide 2. Novel CAG-based promoters that are shorter and more potent than traditional ones, with one variant (C178) showing superior performance in muscle, liver, heart, and brain while being 700 base pairs shorter 3. Research on transcription factor binding sites (TFBS) to enhance synthetic promoter activity, identifying optimal combinations for gene expression 4. Development of optimized AAV-hUPF1 gene therapy for ALS and FTD, showing improved efficacy in multiple disease models while reducing construct size by 1.5kb

#MGTX MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

www.stocktitan.net/news/MGTX/meira-g-tx-ann...

MeiraGTx Reports First Quarter 2025 Financial and Operational Results MeiraGTx (MGTX) reported significant Q1 2025 developments, highlighted by a $200 million strategic collaboration with Hologen AI and formation of Hologen Neuro AI Ltd joint venture with $230 million additional committed capital. Key achievements include: FDA's RMAT designation for AAV-GAD Parkinson's treatment, positive Phase 2 data showing disease-modifying effects, and alignment with FDA on Phase 2 AQUAx2 study for radiation-induced xerostomia. The company reported breakthrough results in LCA4 treatment, with 11 out of 11 children showing meaningful responses, leading to plans for Marketing Authorization filing. The Phase 3 LUMEOS trial for X-linked Retinitis Pigmentosa showed positive secondary endpoints despite missing primary endpoint. MeiraGTx continues advancing its riboswitch technology platform and maintains strong manufacturing capabilities with renewed MHRA licenses.

#MGTX MeiraGTx Reports First Quarter 2025 Financial and Operational Results

www.stocktitan.net/news/MGTX/meira-g-tx-rep...

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease MeiraGTx (NASDAQ: MGTX) has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD, a one-time gene therapy treatment for Parkinson's disease. The designation was granted based on positive data from three clinical studies, including a Phase 1 dose-escalating study (n=12) and two double-blind, sham-controlled Phase 2 studies (n=45 and n=14). The therapy demonstrated significant clinical benefits in motor function (UPDRS Part 3) and, through AI analysis with partner Hologen, showed evidence of disease-modifying changes in brain circuitry. The RMAT designation provides benefits similar to Fast Track and Breakthrough Therapy designations, enabling expedited development, increased FDA interaction, and potential routes to accelerated approval and Priority Review.

#MGTX MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

www.stocktitan.net/news/MGTX/meira-g-tx-gra...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Thu Mar 13th - #YSXT #AVAH #UFG #MFIN #RGC #MGTX #PFC #MIRA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

MeiraGTx Lands Massive $430M AI Deal While Hitting 100% Success in Gene Therapy Trial Gene therapy leader MeiraGTx secures $430M through Hologen AI partnership, achieves 100% response in LCA4 treatment, and advances Parkinson's therapy with positive data. Funded through 2027.

#MGTX MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

www.stocktitan.net/news/MGTX/meira-g-tx-rep...

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy MeiraGTx announced groundbreaking results published in The Lancet for their gene therapy treatment rAAV8.hRKp.AIPL1 targeting Leber Congenital Amaurosis 4 (LCA4), a severe form of inherited blindness. The clinical study demonstrated remarkable efficacy in all 11 treated children who were legally blind at birth.The first cohort of 4 children received unilateral treatment, showing improved visual acuity from light perception to 0.9 LogMAR. A second cohort of 7 children received bilateral treatment, with all participants showing substantial benefits. The treatment demonstrated protection against progressive retinal degeneration without serious adverse effects.Following these exceptional results, MeiraGTx plans to submit a Marketing Authorization Application to the MHRA under exceptional circumstances, with no additional clinical data required. The company is also engaging with the FDA for expedited approval in the United States. The treatment has received orphan drug and rare pediatric disease designations from the FDA and orphan designation from the European Commission.

#MGTX MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

www.stocktitan.net/news/MGTX/meira-g-tx-ann...

EXCUSE ME
2025 already throwing another bowl cut man with swords at me
#mgtx #kiritoarima

Still can't believe I found marriagetoxin merch in the wild in Japan
#mgtx

MeiraGTx Secures Fourth FDA Rare Pediatric Disease Designation for Gene Therapy Treatment MeiraGTx's AAV8-RK-RetGC program for LCA1 receives FDA rare pediatric status. Fourth designation in 3 months could unlock valuable Priority Review Voucher worth up to $158M.

#MGTX MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

www.stocktitan.net/news/MGTX/meira-g-tx-rec...

desenho de mei kinosaki (do mangá marriage toxin) tirando uma selfie dentro do carro, ela está tampando um sorriso com as mãos. ela tem cabelos longos e loiro, seus olhos são rosa e está vestindo um vestido branco com gola alta roxa. tem um texto em inglês que traduzindo diz "quando ele está copiando seus 'snaps' então você faz este movimento".

desenho de mei kinosaki (do mangá marriagetoxin) tirando uma selfie flexionando seu braço esquerdo. ela tem o cabelo longo e loiro, e está vestindo uma blusa de manga comprida preta. seu quarto no fundo está meio bagunçado.

desenho do hikaru gero (do mangá marriagetoxin) tirando uma selfie flexionando seu braço esquerdo. ele tem cabelo curto e azul escuro, usa óculos e uma camiseta azul com detalhes vermelhos, seu braço é musculoso com algumas cicatrizes. tem um texto que diz "boom shakalaka yess gawd".

aquela trend do ttk com os gerosaki

#BRart #marriagetoxin #mgtx #gerosaki

I couldn't tell you what marriagetoxin is about even if I tried
#mgtx

excited for marriagetoxin part-time job arc
#mgtx

Just In: ( NASDAQ: #MGTX ) MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

#StockMarket #News

The authors really wanted to make sure we know Teruaki is gay with that bonus chapter, huh?
#mgtx #マリッジトキシン

Come read marriagetoxin where we all collectively lose our shit every Tuesday
#marriagetoxin #マリッジトキシン #meikinosaki #城崎メイ #mgtx

BREAKING NEWS: ( NASDAQ: #MGTX ) MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease

#StockMarket #News